Abstract: This invention relates to a hydroxamate metalloprotease inhibitor compound for use in a method of diagnosing or treating cancer, inflammatory diseases or Alzheimer's disease. The compound comprises a zinc-chelating N-hydroxamate moiety radiolabeled with a radionuclide. Radiolabeled compounds of the invention may be used in targeted radionuclide therapy wherein a patient is treated with a compound of the invention comprising a diagnostic radionuclide to identify the presence of a cancer or disease, followed by treatment with a compound of the invention comprising a therapeutic radionuclide to treat said cancer or disease.

Abstract: This invention relates new radiopharmaceutical conjugates for use in improved methods of diagnosis and treatment of cancer. The radiopharmaceutical conjugate comprises, in sequence: a metabolite that targets tumour cells, bound to a chelating agent capable of containing a radionuclide, bound to a linker capable of binding with an EPR agent in vitro or in vivo; or a chelating agent capable of containing a radionuclide, bound to a metabolite that targets tumour cells, bound to a linker capable of binding with an EPR agent in vitro or in vivo. The radiopharmaceutical conjugates of the present invention provide active and passive targeted radio nuclide delivery systems that can help to improve the biodistribution and pharmacological toxicity of the radiopharmaceuticals used for the diagnosis and therapy of cancer.

Abstract: A system is provided for adjusting power provided over a channel to a device. The system can include power sourcing equipment and a sub-system. The power sourcing equipment can provide power to a powered device via a channel. The sub-system can determine an amount by which to increase the power based on a resistance of the channel. The power sourcing equipment or the powered device can adjust the power (or load) in response to a command from the sub-system. The sub-system can include at least one measurement device and a processor. The measurement device can measure an output voltage of the power sourcing equipment, an input voltage of the powered device, and a current on the channel. The processor can determine the resistance of the channel based on the output voltage, the input voltage, and the current. The processor can output a command specifying an increase or decrease in the level of power supplied by the power sourcing equipment.

Abstract: This invention relates new radiopharmaceutical conjugates for use in improved methods of diagnosis and treatment of cancer. The radiopharmaceutical conjugate comprises, in sequence: a metabolite that targets tumour cells, bound to a chelating agent capable of containing a radionuclide, bound to a linker capable of binding with an EPR agent in vitro or in vivo; or a chelating agent capable of containing a radionuclide, bound to a metabolite that targets tumour cells, bound to a linker capable of binding with an EPR agent in vitro or in vivo. The radiopharmaceutical conjugates of the present invention provide active and passive targeted radio nuclide delivery systems that can help to improve the biodistribution and pharmacological toxicity of the radiopharmaceuticals used for the diagnosis and therapy of cancer.

Abstract: A system is provided for adjusting power provided over a channel to a device. The system can include power sourcing equipment and a sub-system. The power sourcing equipment can provide power to a powered device via a channel. The sub-system can determine an amount by which to increase the power based on a resistance of the channel. The power sourcing equipment or the powered device can adjust the power (or load) in response to a command from the sub-system. The sub-system can include at least one measurement device and a processor. The measurement device can measure an output voltage of the power sourcing equipment, an input voltage of the powered device, and a current on the channel. The processor can determine the resistance of the channel based on the output voltage, the input voltage, and the current. The processor can output a command specifying an increase or decrease in the level of power supplied by the power sourcing equipment.

Abstract: A system is provided for adjusting power provided over a channel to a device. The system can include power sourcing equipment and a sub-system. The power sourcing equipment can provide power to a powered device via a channel. The sub-system can determine an amount by which to increase the power based on a resistance of the channel. The power sourcing equipment or the powered device can adjust the power (or load) in response to a command from the sub-system. The sub-system can include at least one measurement device and a processor. The measurement device can measure an output voltage of the power sourcing equipment, an input voltage of the powered device, and a current on the channel. The processor can determine the resistance of the channel based on the output voltage, the input voltage, and the current. The processor can output a command specifying an increase or decrease in the level of power supplied by the power sourcing equipment.

Abstract: A system is provided for adjusting power provided over a channel to a device. The system can include power sourcing equipment and a sub-system. The power sourcing equipment can provide power to a powered device via a channel. The sub-system can determine an amount by which to increase the power based on a resistance of the channel. The power sourcing equipment or the powered device can adjust the power (or load) in response to a command from the sub-system. The sub-system can include at least one measurement device and a processor. The measurement device can measure an output voltage of the power sourcing equipment, an input voltage of the powered device, and a current on the channel. The processor can determine the resistance of the channel based on the output voltage, the input voltage, and the current. The processor can output a command specifying an increase or decrease in the level of power supplied by the power sourcing equipment.

Abstract: A system is provided for adjusting power provided to a device. The system can include power sourcing equipment and a sub-system. The power sourcing equipment can provide power to a powered device via a channel. The sub-system can determine an amount by which to increase the power based on a resistance of the channel. The power sourcing equipment or the powered device can adjust the power (or load) responsive to a command from the sub-system. The sub-system can include a measurement device and a processor. The measurement device can measure an output voltage of the power sourcing equipment, an input voltage of the powered device, and a current on the channel. The processor can determine the resistance of the channel based on the output voltage, the input voltage, and the current. The processor can output a command specifying an increase or decrease in power supplied by the power sourcing equipment.

Abstract: Organosulfur compounds of the general formula (2) are described, wherein R1 and R2 are linear or branched C1-C5 alkyl; linear or branched C1-C5 alkenyl with the proviso that R1 is not prop-1-enyl (allyl); substituted linear or branched C1-C5 alkenyl or substituted linear or branched C1-C5 alkyl, in which the substituents are selected from OR3, NR4R5, COOR6, CON—R7R8, in which R3 is selected from H, COR9, para-methoxybenzyl and trialkylsilyl, in which R9 is alkyl or substituted alkyl; R4 N and R5 are alkyl or R4 and R5 together form a phthalimido group; R6 is alkyl or substituted alkyl; and R7 and R8 are alkyl or substituted alkyl; substituted or unsubstituted aromatic specifically where R1 and R2 are benzyl, para-methoxybenzyl and/or ortho,para-methoxybenzyl and substituted or unsubstituted heteroaromatic. The compounds can be used for inhibiting the growth of tumor cells and for treating cancer. A pharmaceutical composition and a method of preparing the compounds are also described.

Abstract: The present invention relates to compounds, in particular, dual antagonists comprising a nucleoside reverse transcriptase inhibitor (NRTI) or a nucleoside competitive reverse transcriptase inhibitor and a non-nucleoside reverse transcriptase inhibitor (NNRTI), linked together using a chemical linker, which may be used to inhibit HIV (HIV-1) reverse transcriptase and in the treatment of HIV infections, more severe cases of HIV infections, including ARC and AIDS, including reducing the likelihood of these infections and disease states.

Abstract: A system is provided for adjusting power provided to a device. The system can include power sourcing equipment and a sub-system. The power sourcing equipment can provide power to a powered device via a channel. The sub-system can determine an amount by which to increase the power based on a resistance of the channel. The power sourcing equipment or the powered device can adjust the power (or load) responsive to a command from the sub-system. The sub-system can include a measurement device and a processor. The measurement device can measure an output voltage of the power sourcing equipment, an input voltage of the powered device, and a current on the channel. The processor can determine the resistance of the channel based on the output voltage, the input voltage, and the current. The processor can output a command specifying an increase or decrease in power supplied by the power sourcing equipment.

Abstract: The present invention relates to compounds, in particular, dual antagonists comprising a nucleoside reverse transcriptase inhibitor (NRTI) or a nucleoside competititive reverse transcriptase inhibitor and a non-nucleoside reverse transcriptase inhibitor (NNRTI), linked together using a chemical linker, which may be used to inhibit HIV (HIV-1) reverse transcriptase and in the treatment of HIV infections, more severe cases of HIV infections, including ARC and AIDS, including reducing the likelihood of these infections and disease states.

Abstract: Organosulfur compounds of the general formula (2) are described, wherein R1 and R2 are linear or branched C1-C5 alkyl; linear or branched C1-C5 alkenyl with the proviso that R1 is not prop-1-enyl (allyl); substituted linear or branched C1-C5 alkenyl or substituted linear or branched C1-C5 alkyl, in which the substituents are selected from OR3, NR4R5, COOR6, CON—R7R8, in which R3 is selected from H, COR9, para-methoxybenzyl and trialkylsilyl, in which R9 is alkyl or substituted alkyl; R4 N and R5 are alkyl or R4 and R5 together form a phthalimido group; R6 is alkyl or substituted alkyl; and R7 and R8 are alkyl or substituted alkyl; substituted or unsubstituted aromatic specifically where R1 and R2 are benzyl, para-methoxybenzyl and/or ortho,para-methoxybenzyl and substituted or unsubstituted heteroaromatic. The compounds can be used for inhibiting the growth of tumour cells and for treating cancer. A pharmaceutical composition and a method of preparing the compounds are also described.

Abstract: A process for the production of optically enriched (R)- or (S)-albuterol or (R)- or (S)-albuterol salts by the resolution of a novel ketal derivative 2-(N-t-butylamino)-1-(+2,2-dimethyl-1,2-benzodioxin-6-yl) ethanol, with a chiral tartaric acid derivative.